The Life Sciences team advised Duality Biologics (Suzhou) Co. Ltd. on its exclusive license and collaboration agreements for two antibody-drug conjugate (“ADC”) assets to develop, manufacture and commercialize the two assets globally with BioNTech SE (Nasdaq: BNTX), excluding Mainland China, Hong Kong Special Administrative Region and Macau Special Administrative Region.
With this collaboration, ADCs will become an additional drug class in BioNTech’s oncology portfolio with the aim to further support BioNTech’s mission of developing highly efficacious therapies for cancer patients at every stage of disease.
DualityBio is a clinical-stage company focusing on the discovery and development of the next generation ADC therapeutics for patients with cancer and autoimmune diseases.
BioNTech is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases.
For more details, read the press release